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Abstract
Background & Aims: Non- alcoholic fatty liver disease is an epidemic. Identifying modi-
fiable risk factors for non- alcoholic fatty liver disease development is essential to de-
sign effective prevention programmes. We tested whether 25- year patterns of body 
mass index change are associated with midlife non- alcoholic fatty liver disease.
Methods: In all, 4423 participants from Coronary Artery Risk Development in Young 
Adults, a prospective population- based biracial cohort (age 18- 30), underwent body 
mass index measurement at baseline (1985- 1986) and 3 or more times over 25 years. 
At Year 25, 3115 had liver fat assessed by non- contrast computed tomography. Non- 
alcoholic fatty liver disease was defined as liver attenuation ≤40 Hounsfield Units 
after exclusions. Latent mixture modelling identified 25- year trajectories in body mass 
index per cent change (%Δ) from baseline.
Results: We identified four distinct trajectories of BMI%Δ: stable (26.2% of cohort, 
25- year BMI %Δ = 3.1%), moderate increase (46.0%, BMI%Δ = 21.7%), high increase 
(20.9%, BMI%Δ = 41.9%) and extreme increase (6.9%, BMI%Δ = 65.9%). Y25 non- 
alcoholic fatty liver disease prevalence was higher in groups with greater BMI %Δ: 
4.1%, 9.3%, 13.0%, and 17.6%, respectively (P- trend <.0001). In multivariable analy-
ses, participants with increasing BMI%Δ had increasingly greater odds of non- alcoholic 
fatty liver disease compared to the stable group: OR: 3.35 (95% CI: 2.07- 5.42), 7.80 
(4.60- 13.23) and 12.68 (6.68- 24.09) for moderate, high and extreme body mass index 
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1  | INTRODUCTION
Non- alcoholic fatty liver disease (NAFLD) is the most common cause 
of chronic liver disease in both children and adults, affecting approxi-
mately 30% of the population.1,2 NAFLD represents a spectrum of 
liver conditions that are associated with differential risk for the de-
velopment of cirrhosis,3 liver cancer,4 need for liver transplantation5 
and cardiovascular disease.6 In addition, mortality is up to 69% higher 
among persons with NAFLD compared to persons without NAFLD.7 
Thus, improving our understanding of how to prevent NAFLD has the 
potential to save millions of lives worldwide.
Non- alcoholic fatty liver disease is the hepatic manifestation of the 
metabolic syndrome, and being overweight or obese is associated with 
greater odds of having NAFLD.3,8 Weight gain throughout adulthood, as 
opposed to weight at a single time point, has been reported to be a risk 
factor for various lifestyle- related diseases including diabetes9 and car-
diovascular diseases.10-12 However, little is known about objective long- 
term weight patterns and NAFLD prevalence, especially among a young, 
contemporary and racially diverse population.13,14 It remains unclear 
whether long- term patterns of weight gain through younger adulthood, 
regardless of concurrent body mass index (BMI) or weight category (e.g. 
normal weight, overweight or obese), adversely influence NAFLD preva-
lence in middle age. Recognition of patterns of weight change over time 
may allow earlier identification of patients who are at risk for developing 
NAFLD and optimize strategies aimed at primary NAFLD prevention.
We therefore sought to examine the association of BMI trajectories 
(e.g. patterns of change over time) among young adults (age 18- 30 years) 
over 25 years with NAFLD defined by computed tomography (CT) in mid-
dle age (43- 55 years). We hypothesized that multiple different trajectories 
of BMI change exist throughout adulthood, and that those groups with 
greater BMI increase throughout adulthood would have a higher preva-
lence of NAFLD in middle age, independent of baseline or concurrent BMI.
2  | METHODS
2.1 | Study sample
The Coronary Artery Risk Development in Young Adults (CARDIA) 
study is an on- going longitudinal cohort study of 5115 biracial men 
and women from 4 metropolitan populations. Participants were 18- 
30 years of age at enrolment (1985- 1986, exam year 0). Recruitment 
was balanced within each centre by sex, age, race and education. 
Participants have been followed at 9 examinations for more than 
30 years with collection of detailed clinical data, including non- contrast 
CT measurement of liver fat at year 25 (2010- 2011). Retention rates 
among survivors for the in- person examinations have been high (Y2, 
90%; Y5, 86%; Y7, 81%; Y10, 77%; Y15, 74%; Y20, 72%; Y25, 72%; 
Y30, 71%) and >90% of initial participants have maintained contact 
over time.15 Participants provided written informed consent at each 
examination, and institutional review boards from each field cen-
tre (University of Alabama at Birmingham, Birmingham, Alabama; 
Northwestern University, Chicago, Illinois; University of Minnesota, 
Minneapolis, Minnesota; and Kaiser Permanente, Oakland, California) 
approved the study annually.
Trajectories of per cent change (%Δ) in BMI relative to baseline 
were modelled among all 4423 participants with BMI measured at 
baseline and at 3 or more follow- up examinations. BMI values at ex-
aminations at which the participant was pregnant (n = 266) were ex-
cluded. Of the 3430 participants with repeat BMI measures at Y25, 
3115 had liver fat assessed. We excluded those with self- reported 
increase, respectively. Associations were only moderately attenuated when adjusted 
for baseline or Y25 body mass index.
Conclusions: Trajectories of weight gain during young adulthood are associated with 
greater non- alcoholic fatty liver disease prevalence in midlife independent of meta-
bolic covariates and baseline or concurrent body mass index highlighting the impor-
tance of weight maintenance throughout adulthood as a target for primary non- alcoholic 
fatty liver disease prevention.
K E Y W O R D S
NAFLD, NASH, obesity, prevention
Key points
• NAFLD is an epidemic associated with increased liver and 
non-liver-related morbidity and mortality.
• Overweight and obesity weight categories are highly as-
sociated with NAFLD and early identification of modifia-
ble risk factors is an important strategy to decrease the 
NAFLD burden.
• Increasing patterns of weight change throughout adult-
hood are associated with differential risk for NAFLD in 
midlife independent of starting or concurrent weight or 
weight category.
• Strategies aimed at weight maintenance through young 
adulthood, rather than weight loss attempts later, are 
likely to be most successful at preventing NAFLD.
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cirrhosis or viral hepatitis (n = 54), risk factors for chronic liver disease 
(e.g. intravenous drug use, n = 81) or causes of secondary hepatic ste-
atosis: alcohol consumption ≥7 drinks/wk in women and ≥ 14 drinks/
wk in men (n = 280),16 human immunodeficiency virus (n = 23), and 
medications known to cause hepatic steatosis (e.g. valproic acid, meth-
otrexate, tamoxifen, steroids, amiodarone) (n = 27). The remaining 
2650 formed the NAFLD- eligible sample population (Figure 1).
2.2 | Measurements
Standardized protocols for data collection were used across study 
centres and have previously been described.15,17 Weight and height 
were measured with participants wearing light clothes and no shoes 
at each of the 8 examinations. Body weight was measured to the 
nearest 0.2 kg with a calibrated balance- beam scale. Height was 
measured with a vertical ruler to the nearest 0.5 cm. BMI was cal-
culated as weight in kilograms divided by height in meters squared. 
Waist circumference (WC) was measured in duplicate to the nearest 
0.5 cm around the minimal abdominal girth identified laterally mid-
way between the iliac crest and the lowest portion of the rib cage 
and anteriorly midway between the xiphoid process and the umbili-
cus parallel to the floor. Hip circumference was measured in duplicate 
to the nearest 0.5 cm at the level of the pubis symphysis anteriorly 
and posteriorly at the level of the maximal protrusion of the gluteal 
muscles. Participants were asked to fast for 12 hours and to avoid 
smoking and heavy physical activity for 2 hours before each examina-
tion. Overweight was defined as BMI 25- 29.9 kg/m2, class I obesity as 
BMI 30- 34.9 kg/m2, class II as BMI 35- 39.9 kg/m2 and class III obesity 
as BMI ≥ 40 kg/m2. The metabolic syndrome was defined according 
to Adult Treatment Panel III criteria.18 To quantify physical activity 
(reported as exercise units [EU]), the CARDIA physical activity history 
questionnaire was used, which was an interviewer- based self- report 
of duration and intensity of participation in 13 categories of exercise 
over the previous 12 months.17 As a reference, 300 EU approximates 
150 minutes of moderate- intensity activity per week or 30 minutes of 
moderate- intensity activity 5 days per week.17 All CARDIA protocols 
are publicly available at: http://www.cardia.dopm.uab.edu.
The CT protocol included the heart and abdomen using a non- 
contrast CT scan performed using GE (GE 750HD 64 and GE 
LightSpeed VCT 64 Birmingham and Oakland Centers, respectively; GE 
Healthcare, Waukesha, WI, USA) or Siemens (Sensation 64, Chicago 
and Minneapolis Centers; Siemens Medical Solutions, Erlangen, 
Germany) multi- detector CT scanners and has been described previ-
ously.19 Quality control and image analysis were performed at a core 
reading centre (Wake Forest University Health Sciences, Winston- 
Salem, NC).
The primary outcome was NAFLD at Y25 defined as liver attenu-
ation (LA) ≤40 Hounsfield Units (equivalent to moderate- severe fat)20 
after exclusion of other causes of liver fat (Figure 1).19 LA was mea-
sured in the right lobe of the liver and was reported as the average 
of 9 measurements on 3 CT slices using circular regions of interest of 
2.6 cm2. The intraclass correlation coefficient between different read-
ers on a random selected sample of 156 participants was 0.975 for LA, 
indicating high reproducibility of CT measured LA.
2.3 | Statistical analysis
Trajectories in BMI, WC and waist- to- hip ratio (WHR) %Δ were mod-
elled among all participants (N = 4423) using data from each examina-
tion attended. The %Δ was modelled rather than absolute values of 
increase since %Δ more appropriately represents baseline and rela-
tive change values. We used latent class models to identify subgroups 
that share a similar trajectory in BMI, WC or WHR %Δ.21 The optimal 
number of trajectory classes was determined using the Bayesian in-
formation criterion such that no group included <5% of the popula-
tion. To estimate the association of trajectory group with prevalent 
NAFLD, trajectory group membership was included as an independ-
ent variable in a logistic regression model examining predictors of Y25 
NAFLD. To account for the uncertainty in BMI %Δ trajectory group 
assignment, we calculated the posterior predicted probability for each 
individual of being a member in each of the classes.22 Participants 
were assigned to the trajectory group for which they had the greatest 
posterior predictive probability. Models were sequentially adjusted 
a priori for potential confounders including demographics (baseline 
age, sex, race, education, centre), cumulative burden of metabolic 
risk factors (cumulative systolic blood pressure [SBP], number of vis-
its with blood pressure medications, cumulative triglycerides, cumu-
lative years of diabetes, pack- years of cigarette smoking exposure, 
cumulative alcohol use [drinks/d], cumulative physical activity [EU 
per year]), and BMI at baseline (Y0) or at the time of NAFLD assess-
ment (Y25). Cumulative SBP, alcoholic beverages, physical activity 
and triglycerides were calculated by summing the product of the 
F IGURE  1 Study population. Abbreviations: CT, computed 
tomography; HIV, human immunodeficiency virus. *Alcohol use 
was defined as ≥7 drinks/wk in women, ≥14 drinks/wk in men. 
†Medications = valproic acid, methotrexate, tamoxifen, steroids and 
amiodarone
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average SBP (or triglycerides or alcohol or physical activity) and the 
time interval (in years) between 2 consecutive examinations over the 
25 years. Interaction terms were assessed between trajectory group 
membership and race and sex. We compared the predictive utility of 
BMI %Δ trajectory group compared with other adiposity measures 
(WC or WHR) using the C statistic derived from the logistic regression 
models. Missing data were excluded from analyses. All variables ana-
lysed had <1% missing data. All analyses were completed using SAS 
software version 9.4 (SAS Institute Inc., Chicago, IL, USA). Two- sided 
P < .05 was considered statistically significant.
3  | RESULTS
3.1 | Fat distribution and metabolic characteristics
Four discrete trajectories in BMI %Δ from young adulthood to 
middle age were identified (Figure 2). In general, BMI increased 
over time in the majority of participants: only 26.2% of the cohort 
(n = 1159) maintained stable BMI %Δ throughout follow- up (stable; 
BMI %Δ = 3.1% ± 9.1% [mean ± SD]); 46.0% (n = 2035) had mod-
erate BMI increase (moderate increase; BMI %Δ = 21.7% ± 9.7%), 
20.9% (n = 923) had high BMI increase (high increase; BMI 
%Δ = 41.8% ± 13.8%) and 6.9% (n = 306) had an extreme BMI in-
crease (extreme increase; BMI %Δ = 65.9% ± 19.3%), with a notable 
early rapid %Δ in BMI. The observed BMI %Δ corresponded to an av-
erage weight gain over 25 years of 1.9 ± 8.0, 15.3 ± 7.5, 29.0 ± 11.0 
and 43.8 ± 14.1 kg in the stable, moderate, high and extreme increase 
groups, respectively.
Participant characteristics at the baseline examination according 
to BMI %Δ trajectory group are presented in Table 1. Individuals with 
a higher BMI %Δ trajectory were younger and more likely to be female, 
black and have lower education than the stable group. At Y25, groups 
with greater increases in BMI had a higher prevalence of components 
of the metabolic syndrome manifested by higher diabetes prevalence, 
fasting glucose, HOMA- IR and triglycerides and lower HDL levels 
(Table 2).
At baseline, the majority of participants were normal weight 
(>62%) and the extreme increase group had the smallest proportion of 
obesity (5.6%, Table S1). However, over time, the proportion of over-
weight/obesity increased substantially, particularly among groups with 
substantial %Δ in BMI. Mean BMI at Y25 was 25.9 ± 5.7, 29.5 ± 5.8, 
34.3 ± 7.2 and 38.9 ± 7.3 kg/m2 in the stable, moderate, high increase 
and extreme increase groups, respectively (Table S1).
3.2 | %Δ BMI and NAFLD
Non- alcoholic fatty liver disease prevalence at Y25 was higher with 
increasing BMI change group and was present in 4.1% (n = 38), 9.3% 
(n = 146), 13.0% (n = 93) and 17.6% (n = 39) in the stable, moderate 
increase, high increase and extreme increase groups, respectively (P- 
trend <.0001, Figure S1A). In comparison with individuals in the stable 
group, those in trajectory groups with patterns of increasingly severe 
BMI %Δ had progressively greater odds of having NAFLD even when 
adjusted for demographics, education and cardiovascular risk factors 
(ORs 3.35 [95% CI: 2.07- 5.43], 7.80 [4.60- 13.23] and 12.68 [6.68- 
24.09]) for moderate, high and extreme increase groups, respectively, 
Table 3). These associations were only moderately attenuated when 
adjusted for baseline BMI (Table 3). Associations were attenuated 
more substantially, but remained statistically significant when ad-
justed for Y25 BMI (Table 3).
Figure 3 demonstrates Y25 NAFLD prevalence stratified by weight 
category at baseline according to BMI %Δ trajectory group. Within 
each trajectory group, NAFLD prevalence increased with increasing 
weight category group. However, participants with class I obesity 
who maintained a stable BMI over time were significantly less likely to 
have prevalent NAFLD at Y25 compared with those who were normal 
weight at baseline, but who had an extreme increase in BMI %Δ over 
time (e.g. 6.5% vs 17.9%, P < .0001). Associations were similar, though 
less pronounced, for participants with baseline class II (15.7%) and 
class III (16.2%) obesity who maintained stable weight compared with 
those who were normal weight at baseline with extreme BMI increase 
over time (P < .05 for both, respectively).
We identified a significant interaction between BMI %Δ trajectory 
group with both race and sex on the odds of Y25 NAFLD. Despite this 
statistical interaction, among all race- sex groups the odds of NAFLD 
increased with increasing BMI %Δ trajectories and whereas we ob-
served different magnitudes of association across race- sex groups, the 
direction of the association did not differ. The prevalence of NAFLD 
was low (<5%) in several subgroups, particularly in white females and 
black males with stable BMI (Table S2); thus, the point estimates for 
odds of NAFLD by BMI %Δ trajectory group had poor precision in 
analyses stratified by race and sex (e.g. 95% CI: 14.8- 427.4, Table S3).
3.3 | %Δ Waist circumference and waist- to- hip ratio
Overall patterns of change throughout adulthood were similar when 
we examined the trajectories of %Δ in WC or WHR separately (Figure 
S2). Changes in WC and WHR trajectory groups were highly to mod-
erately correlated with BMI %Δ groups (Spearman r = .82 for WC 
F IGURE  2 Per cent Change (%Δ) Body Mass Index (BMI) 
Trajectories by Age in the Coronary Artery Risk Development in 
Young Adults (CARDIA) Study. Total N = 4423
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and .39 for WHR, P < .0001 for both). Both WC and WHR %Δ were 
similarly associated in a dose- response fashion with NAFLD at Y25 
(Figures S1B and C). As expected, associations with measures of cen-
tral adiposity %Δ and prevalent NAFLD demonstrated similar trends 
as those models that used BMI %Δ (Tables S4 and S5). In the multivari-
able adjusted model, WC %Δ discriminated prevalent NAFLD compa-
rably to BMI %Δ (C statistic, 0.784 for WC and 0.780 for BMI) and 
slightly better than WHR %Δ (C statistic, 0.754).
4  | DISCUSSION
In a large, population- based, prospective study of biracial adults fol-
lowed for 25 years, we identified four trajectories of BMI change 
that were significantly associated with prevalent NAFLD in midlife. 
We found that those groups with greater BMI increase from young 
adulthood to middle age have the greatest odds of having NAFLD in 
midlife, regardless of demographics, the cumulative burden of clini-
cal covariates and weight status at baseline or concurrently. Indeed, 
those who had baseline obesity and had major BMI increases through 
young adulthood had NAFLD prevalence of 28%- 40%; conversely, 
those who had baseline obesity but maintained stable BMI had NAFLD 
prevalence of only 16%. These findings highlight the importance of 
weight maintenance throughout young adulthood, regardless of base-
line weight, as a critical target for the primary prevention of NAFLD.
The current study provides unique insights into long- term patterns 
of change in BMI during early adulthood. Importantly, participants at 
baseline had similar mean BMI values, yet their patterns over time di-
verged markedly. In CARDIA, a large proportion of participants devel-
oped incident obesity over time with increases in BMI in all groups to 
varying degrees. We identified heterogeneous patterns of BMI change 
as separate trajectory groups, thus providing increased understanding 
of lifetime trends in weight. Knowledge of these trajectories through-
out adulthood may allow us to potentially attenuate the NAFLD 
TABLE  1 Baseline characteristics at year 0 by body mass index per cent change (%Δ) trajectory group
Demographic 
characteristicsa Stable N = 1159
Moderate increase 
N = 2035 High increase N = 923
Extreme increase 
N = 306 P valueb
Age, years 26.1 (3.2) 25.5 (3.4) 23.4 (3.5) 21.6 (3.2) <.0001
Race
Blacks 440 (38.0) 949 (46.6) 576 (62.4) 214 (69.9) <.0001
Whites 719 (62.0) 1086 (53.4) 347 (37.6) 92 (30.1)
Sex
Women 605 (52.2) 1058 (52.0) 546 (59.2) 223 (72.9) <.0001
Men 554 (47.8) 997 (48.0) 377 (40.9) 83 (27.1)
Education, years 14.4 (2.4) 14.0 (2.3) 13.3 (1.9) 12.8 (1.7) <.0001
Current smoker 338 (29.3) 585 (28.9) 262 (28.6) 83 (27.3) .08
Alcohol drinker 780 (67.6) 1272 (62.8) 493 (53.7) 144 (47.1) <.0001
Alcohol use, g/d 12.1 (20.2) 9.5 (15.6) 8.1 (18.9) 5.0 (10.2) <.0001
Physical activity, 
exercise units
444.2 (297.8) 397.6 (292.1) 420.6 (301.6) 365.6 (284.9) <.0001
Weight, kg 73.8 (18.3) 70.8 (15.4) 69.8 (15.5) 66.8 (13.2) <.0001
Height, cm 171.2 (9.5) 170.6 (9.4) 169.6 (9.7) 167.7 (8.9) .001
BMI, kg/m2 25.2 (5.9) 24.3 (4.7) 24.3 (4.7) 23.8 (4.1) <.0001
Waist circumference, cm 79.9 (13.2) 77.8 (10.8) 76.2 (10.6) 74.1 (8.6) <.0001
Waist- hip ratio 0.79 (0.07) 0.78 (0.07) 0.76 (0.06) 0.75 (0.07) <.0001
Systolic BP, mm Hg 111.1 (11.2) 110.5 (10.9) 109.6 (10.4) 109.0 (11.6) .001
Diastolic BP, mm Hg 69.6 (9.9) 68.8 (9.6) 67.6 (9.3) 66.6 (9.2) <.0001
Hypertension 62 (5.4) 73 (3.6) 31 (3.4) 11 (3.6) .06
Fasting glucose, mg/dL 84.5 (21.2) 82.3 (14.3) 80.7 (8.4) 80.2 (9.3) <.0001
Diabetes 22 (1.9) 21 (1.0) 3 (0.3) 2 (0.7) .005
Total cholesterol level 179.9 (33.7) 178.4 (33.2) 173.4 (31.1) 168.2 (32.9) <.0001
HDL cholesterol, mg/dL 52.9 (13.3) 52.8 (13.0) 54.2 (13.4) 53.8 (11.8) .04
Triglyceride, mg/dL 80.9 (64.4) 73.1 (43.1) 65.5 (35.6) 59.7 (25.6) <.0001
SD, standard deviation; n, number; BMI, body mass index; BP, blood pressure; HDL, high- density lipoprotein.
All results are presented as mean (SD) or n (%).
aAll variables have <1% missing.
bChi- square test for categorical variables and ANOVA for continuous variables.
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N = 1574 High increase N = 716
Extreme increase 
N = 221 P valueb
Age, years, mean (SD) 51.3 (3.2) 50.7 (3.4) 48.6 (3.6) 46.7 (3.3) <.01
Race, n (%)
Blacks 440 (38.0) 949 (46.6) 576 (62.4) 214 (69.9) <.0001
Whites 719 (62.0) 1086 (53.4) 347 (37.6) 92 (30.1)
Sex
Women 605 (52.2) 1058 (52.0) 546 (59.2) 223 (72.9) <.0001
Men 554 (47.8) 977 (48.0) 377 (40.9) 83 (27.1)
Current smoker 178 (19.4) 263 (16.7) 104 (14.5) 30 (13.6) .11
Alcohol drinker 594 (64.8) 859 (54.6) 328 (45.8) 85 (38.5) <.0001
Alcohol use, g/d 440 (38.0) 949 (46.6) 576 (62.4) 214 (69.9) <.0001
Physical activity, exercise units 402.2 (283.3) 287.5 (244.8) 340.5 (281.1) 222.3 (222.9) <.0001
BMI, kg/m2 25.9 (5.7) 29.5 (5.8) 34.3 (7.2) 38.9 (7.3) <.0001
Waist circumference, cm 85.4 (14.7) 93.9 (13.7) 102.2 (15.2) 109.5 (13.8) <.0001
Waist- to- hip ratio 0.83 (0.09) 0.86 (0.09) 0.87 (0.09) 0.86 (0.08) <.0001
Systolic BP, mm Hg 116.8 (17.1) 119.5 (15.2) 122.8 (16.1) 121.6 (16.6) <.0001
Diastolic BP, mm Hg 71.6 (11.3) 74.6 (10.8) 78.1 (11.0) 78.9 (11.0) <.0001
Hypertension 239 (26.1) 510 (32.4) 300 (41.9) 97 (43.9) <.0001
Fasting glucose, mg/dL 97.8 (33.5) 99.1 (25.6) 101.3 (28.4) 102.4 (26.1) .04
HOMA- IR 3.3 (3.8) 4.2 (3.5) 5.0 (3.9) 6.1 (5.1) <.0001
Diabetes 95 (10.4) 193 (12.3) 97 (13.5) 37 (16.7) .04
Total cholesterol level 192.1 (36.3) 193.2 (37.8) 193.4 (36.5) 183.1 (34.0) .002
HDL cholesterol, mg/dL 65.6 (21.2) 56.3 (16.2) 54.2 (15.7) 51.4 (13.0) <.0001
Triglyceride, mg/dL 99.2 (75.6) 117.2 (91.0) 126.1 (95.2) 113.0 (64.4) <.0001
Liver attenuation, HU 58.2 (9.4) 55.2 (11.8) 53.2 (13.5) 51.5 (12.7) <.0001
SD, standard deviation; n, number; BMI, body mass index; BP, blood pressure; HOMA- IR, Homeostatic model assessment for insulin resistance; HDL, high- 
density lipoprotein; HU, Hounsfield units.
All results are presented as mean (SD) or n (%).
aAll variables have <1% missing.
bChi- square test for categorical variables and ANOVA for continuous variables.
TABLE  3 Odds ratios for the association of BMI %Δ trajectory group with prevalent NAFLD in middle age in CARDIA
BMI %Δ group
Unadjusted Base modela Base model + Y0 BMI Base model + Y25 BMI
N = 2615 N = 2615 N = 2615 N = 2611
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Stable Reference
Moderate increase 2.65 (1.71- 4.09) .005 3.35 (2.07- 5.43) .04 4.40 (2.66- 7.31) .03 2.56 (1.55- 4.21) .69
High increase 4.27 (2.71- 6.73) .0002 7.80 (4.60- 13.23) <.0001 11.38 (6.51- 19.89) <.0001 3.73 (2.13- 6.52) .001
Extreme increase 5.51 (3.22- 9.42) <.0001 12.68 (6.68- 24.09) <.0001 21.18 (10.75- 41.72) <.0001 3.68 (1.83- 7.41) .04
BMI, body mass index; NAFLD, non- alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.
Results presented as Odds Ratio (95% Confidence interval).
NAFLD = liver attenuation ≤40 HU after exclusion for secondary causes of liver fat.
aBase model adjusted for baseline age, sex, race, education, centre, cumulative systolic blood pressure (mm Hg- years), number of years with blood pressure 
medications, cumulative triglycerides (mg/dL- years), cumulative years with diabetes, cumulative alcohol use (drinks/d), physical activity level (exercise 
units- year) and pack- years of cigarette smoking exposure.
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epidemic, highlighting the period of transition from young adulthood 
to middle age as a prime target for health promotion, primordial pre-
vention and long- term disease prevention.
The association between adult weight gain and NAFLD was inde-
pendent of multiple metabolic risk factors associated with histological 
progression of NAFLD. Body weight gain in earlier adulthood (age 25- 
40 years) has been associated with increased markers of insulin resis-
tance compared with later adulthood weight gain (age >40 years).23 In a 
cross- sectional study of 1119 Chinese participants (mean age 47), earlier 
increases in insulin resistance mediated the relationship between adult 
weight gain and NAFLD.13 In addition, BMI increase in earlier adult-
hood is more strongly associated with unfavourable levels of obesity 
biomarkers (e.g. adiponectin) and markers of liver damage (e.g. gamma- 
glutamyl transferase), than BMI gain in later adulthood.23 Therefore, the 
increased NAFLD prevalence in midlife among adults with a steep, early 
increase in BMI (as was observed in our extreme increase trajectory 
group) may in fact be mediated by the systemic influences of visceral 
adiposity. This is supported by the finding that increased WC, a marker 
of visceral adiposity, was highly predictive of prevalent NAFLD.
We observed significant differences in the strength of the as-
sociation of BMI trajectory and NAFLD prevalence by race and sex. 
NAFLD prevalence was highest in white men followed by white 
women, black men and black women, whereas obesity prevalence 
was highest among black women and black men. There are signifi-
cant differences in NAFLD prevalence between racial- ethnic groups 
with a higher risk of severe disease in Hispanics and Whites, and a 
surprisingly low risk in African Americans, for reasons that are not 
entirely known.8,24 Future studies are needed to assess the potential 
impact of adult weight gain among various racial- ethnic populations 
who may be at differential risk for NAFLD despite a high prevalence 
of obesity.
4.1 | Strengths and limitations
Our study has several strengths. The CARDIA study is well- 
positioned to examine longitudinal trends in BMI and its relation-
ship to NAFLD since the cohort began at the start of the obesity 
epidemic (1985- 86), prior to the onset of the NAFLD epidemic, and 
involves a biracial population with a wealth of rigorously measured 
covariates. In addition to our BMI findings, we saw similar trajectory 
patterns with measures of central fat distribution (WC, WHR) with 
greater NAFLD prevalence associated with greatest increases in 
these measures, independent of cumulative comorbidities. Finally, 
we applied innovative statistical methods to examine patterns of 
changes in adiposity in a large, well- characterized cohort of black 
and white Americans.
Several limitations should also be considered when interpreting our 
study results. NAFLD prevalence in CARDIA is somewhat lower than 
what has been reported in other US cohorts. Our NAFLD outcome was 
measured by LA on non- contrast CT which is a relatively insensitive tool 
for liver fat assessment compared to magnetic resonance imaging (e.g. 
MR- PDFF or spectroscopy), which are not available in CARDIA.20,25 
We chose our LA cut- off based on previous studies correlating LA with 
histology, which showed excellent specificity but lower sensitivity for 
the detection of NAFLD.20 Maintaining high specificity minimizes the 
impact of measurement bias; however, our LA cut- off could not detect 
lesser degrees of pathologic steatosis between 5% and 30%. Second, 
CARDIA included a biracial cohort of adults and we observed a lower 
NAFLD prevalence in blacks compared to whites consistent with other 
studies.24 Our cohort also did not ask about Hispanic ethnicity or obtain 
data on genetic polymorphisms including patatin- like phospholipase do-
main containing protein 3 (PNPLA3), which partially explain racial dif-
ferences in NAFLD. Thus, our findings cannot be generalized to other 
ethnic groups. Contemporaneous or baseline laboratory data on hepatic 
function are not available in CARDIA. However, there is no laboratory 
test for NAFLD and serum aminotransferases are often normal despite 
the presence of liver injury.26 NAFLD was also not assessed in CARDIA 
prior to the Y25 follow- up examination and thus, we do not know when 
during adulthood NAFLD may have developed. However, since NAFLD 
is primarily an asymptomatic disease, detection in midlife mirrors clinical 
practice when NAFLD is commonly incidentally found on imaging per-
formed for other reasons.27 It is also possible that some CARDIA partic-
ipants had undiagnosed NAFLD at the baseline examination. However, 
over 62% of NAFLD participants were normal weight at baseline. Finally, 
viral hepatitis status was obtained by self- report, raising the possibility 
of undiagnosed hepatitis, particularly Hepatitis C, within our cohort.
4.2 | Clinical and public health implications
Weight loss has been associated with biochemical,28 radiographic29,30 
and histological31,32 improvements in NAFLD, but initial weight loss 
may be a challenge and maintaining lower weight after weight loss 
is difficult over time.33 Weight loss and physical activity are the rec-
ommended treatments for NAFLD.16 However, efficacy of lifestyle 
intervention is poor due to a lack of patient adherence, programmes 
F IGURE  3 Year 25 non- alcoholic fatty liver disease (NAFLD) 
Prevalence Stratified by Baseline Weight Category and Per 
cent Change (%Δ) in BMI Trajectory Group (Total N at Year 25 
exam = 2650). Class I obesity was defined as body mass index (BMI) 
30- 34.9 kg/m2, class II obesity as BMI 35- 39.9 kg/m2, class III obesity 
as BMI ≥ 30 kg/m2, overweight as BMI 25- 29.9 kg/m2 and normal 
weight as BMI < 25 kg/m2
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designed specifically for patients with liver disease, and financial sup-
port from payers to sustain these programmes long- term.16,34 Finally, 
lifestyle interventions in early adult life are more likely to be successful 
than interventions attempted later in life once lifestyle habits and dis-
eases have further progressed.35 In addition to weight loss as a treat-
ment for obesity (e.g. secondary prevention), our data suggest that 
primary prevention strategies aimed at weight maintenance through 
young adulthood are likely to have a significant impact at preventing 
NAFLD and its consequences. Thus, maintaining weight throughout 
adulthood regardless of starting point (e.g. normal weight, overweight 
or obese) may reduce NAFLD risk in middle age.
5  | CONCLUSION
Our findings imply that the trajectory of BMI change throughout early 
adulthood to midlife – independent of baseline and concurrent BMI – 
provides additional information about the risk of developing NAFLD. 
These associations were independent of key comorbidities and meta-
bolic risk factors. This novel characterization of change in BMI tra-
jectories across a critical period for significant weight gain highlights 
young adulthood as an important target for behaviour and lifestyle 
interventions for primordial prevention of NAFLD. Prevention pro-
grammes that target weight maintenance in early adulthood, regard-
less of starting weight or weight category, may be more effective for 
NAFLD prevention than programmes that target weight loss after the 
disease has developed in later life.
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